How well does Tecentriq work on EGFR positive patients who have progressed on Tarceva and/or Tagrisso? I noticed that Tecentriq can be used for EGFR patients and am wondering if there is any promise there.
At this time there hasn’t been a lot of benefit shown from PD-L1 inhibitors against those with an EGFR mutation. It appears that those who have a significant smoking history do best. This is possibly due to the fact that smokers cultivate many mutations over the years and this is what the PD-1 and PD-L1 inhibitors respond to. Those with an EGFR mutation most often have little to no smoking history and the EGFR mutation seems to be the only (driver) mutation that drives the cancer. There seem to be a connection but again we don’t fully understand the mechanisms of action.
There are currently clinical trials testing combinations of drugs with immunotherapies that have had promising results for those with single driver mutations. It may be possible to join one. It’s usually best to join a trial when trying an unproven therapy for many reason. One reason is those who administer and collect the data keep a vigilant watch over the participants to avoid adverse affects of an untested treatment. Costs as well play a part. Insurance usually won’t pay for an unproven treatment.